



## Correction: Chromogranin A and its derived peptides: potential regulators of cholesterol homeostasis

Dhanya R. Iyer<sup>1</sup> · Janani Venkatraman<sup>1</sup> · Emeline Tanguy<sup>2</sup> · Nicolas Vitale<sup>2</sup> · Nitish R. Mahapatra<sup>1</sup>

Accepted: 22 September 2023 / Published online: 6 November 2023  
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023

**Correction: Cellular and Molecular Life Sciences  
(2023) 80:271**

<https://doi.org/10.1007/s00018-023-04908-3>

In Table 1 of this article, the heading of the 5th column should be read as “apolipoproteins” instead of “lipoproteins”.

In the last column (pathophysiological implications) of the first row (Chylomicrons), “dietarytriglycerides” should be read as “dietary triglycerides”.

In the 2nd column of the last row the size of Lp(a) mentioned as 30 should be read as ~ 30.

The corrected Table 1 is given below.

The original article has been corrected.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

The original article can be found online at <https://doi.org/10.1007/s00018-023-04908-3>.

---

✉ Nicolas Vitale  
vitalen@unistra.fr

Nitish R. Mahapatra  
nmahapatra@iitm.ac.in

<sup>1</sup> Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai 600036, India

<sup>2</sup> Institut des Neurosciences Cellulaires et Intégratives, CNRS UPR 3212 and Université de Strasbourg, 5 Rue Blaise Pascal, 67000 Strasbourg, France

**Table 1** Circulatory forms of cholesterol

Lipoprotein	Size (nm)	Density (g/ml)	Major lipids	Major apolipoproteins	Pathophysiological implications
Chylomicrons	75–1200	<0.930	Triglycerides	Apo B-48; Apo C-I, C-II, C-III; Apo E; Apo A-I, A-II, A-IV, A-V	Transport of dietary triglycerides and cholesterol, pro-atherogenic
Chylomicron remnants	30–80	0.930–1.006	Triglycerides, cholesterol	Apo B-48, Apo E	Pro-atherogenic
VLDL	30–80	0.930–1.006	Triglycerides	Apo B-100; Apo E; Apo C-I, C-II, C-III; Apo A-V	Pro-atherogenic
IDL	25–35	1.006–1.019	Triglycerides, cholesterol	Apo B-100; Apo E; Apo C	Pro-atherogenic
LDL	18–25	1.019–1.063	Cholesterol	Apo B-100	Hypertriglyceridemia, type 2 diabetes, obesity, inflammation, pro-atherogenic
HDL	5–12	1.063–1.210	Cholesterol, phospholipids	Apo A-I, A-II, A-IV, A-V; Apo C-I, C-II, C-III; Apo E	Anti-oxidant, anti-thrombotic, anti-apoptotic, anti-inflammatory, anti-atherogenic
Lp (a)	~30	1.055–1.085	Cholesterol	Apo B-100; Apo (a)	Pro-atherogenic